How Cytokinetics Defied Biotech’s Odds To Reach FDA Approval [Forbes]
Cytokinetics, Incorporated (CYTK)
Last cytokinetics, incorporated earnings: 3/3 04:00 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.cytokinetics.com/investor-overview
Company Research
Source: Forbes
IPO activity is beginning to return , with biotech listings raising $1.7 billion in Q1 2026, the strongest quarter since 2021. It is into that selective rebound that Cytokinetics arrives with something rare in biotech: a first FDA approval after nearly three decades in development. The company recently secured approval for Myqorzo (aficamten), marking the culmination of a 27-year program that began as early-stage muscle biology research and has now become a commercial therapy for hypertrophic cardiomyopathy. The condition affects as many as 200,000 patients in the U.S., and a similar number in Europe. The milestone is not just a product launch; it is also a test case for whether long-horizon, highly focused biotech strategies can survive an industry defined by failure. For CEO Robert Blum, the approval is validation of a deliberate model of company-building that prioritizes scientific depth, financial discipline, and long-term persistence over breadth or speed. “It's not unprecede
Show less
Read more
Impact Snapshot
Event Time:
CYTK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CYTK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CYTK alerts
High impacting Cytokinetics, Incorporated news events
Weekly update
A roundup of the hottest topics
CYTK
News
- Cytokinetics Announces Nine Upcoming Presentations at the European Society of Cardiology Heart Failure 2026 CongressGlobeNewswire
- Cytokinetics: Strong Story, But Valuation Leaves Limited Upside [Seeking Alpha]Seeking Alpha
- Cytokinetics (CYTK) had its "sell (d-)" rating reaffirmed by <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Cytokinetics to Announce First Quarter Results on May 5, 2026GlobeNewswire
- Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)GlobeNewswire
CYTK
Earnings
- 2/24/26 - Miss
CYTK
Sec Filings
- 4/29/26 - Form SCHEDULE
- 4/29/26 - Form 4
- 4/21/26 - Form 4
- CYTK's page on the SEC website